MULTICENTER PROBE STUDY-4; COMPARISON OF THE EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS

MULTICENTER PROBE STUDY-4; COMPARISON OF THE EFFECTS OF ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS - MUSCAT-4

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012768

Enrollment

Registered

2014-01-06

Start date

2013-09-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

Switch the previous ARBs (Losartan, Candesartan, Valsartan, Telmisartan, Irbesartan) to Olmesartan which is allowed to increase the maximum dosage, then treat the patients for 4 months. Switch the pre

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The uncontrolled out-patients with hypertension who have treated with ARBs (Losartan, Candesartan, Valsartan, Telmisartan and Irbesartan) except Olmesartan for more than 3 months

Exclusion criteria

Exclusion criteria: The patients with, 1)severe renal failure (sCr>2.0mg/dl), 2)severe hepatic dysfunction (AST/ALT>100IU/l), 3)the history of severe side effect of ARB 4)pregnancy or lactation, 5)malignancy or other poor-prognosis disease, 6)those who are considered inappropriate by physician

Design outcomes

Primary

Measure	Time frame
Change in the clinic and home blood pressure	—

Secondary

Measure	Time frame
renal function (Cr, eGFR, K), u-Alb/Cr, u-Na/Cr, lipid profile (LDL-C, HDL-C, T.Cho), others markers, and final dosage of the drug	—

Countries

Japan

Contacts

Public ContactHaruhito Adam Uchida

Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences Department of Medicine and Clinical Sciences

sannai@cc.okayama-u.ac.jp086-235-7235

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026